Home/Pipeline/MSIcare Platform Development & Validation

MSIcare Platform Development & Validation

Pan-Cancer MSI Detection (Colorectal, Endometrial, Gastric, etc.)

CommercialActive

Key Facts

Indication
Pan-Cancer MSI Detection (Colorectal, Endometrial, Gastric, etc.)
Phase
Commercial
Status
Active
Company

About MSInsight

MSInsight is a Paris-based diagnostics company focused on transforming cancer care through the precise detection of microsatellite instability (MSI). Its proprietary AI-powered software platform, MSIcare, analyzes next-generation sequencing (NGS) data to provide actionable insights for treatment selection, primarily for solid tumors like colorectal, endometrial, and gastric cancers. The company targets NGS laboratories, clinical practitioners, and the pharmaceutical industry, aiming to integrate its tool into standard oncology workflows to enable personalized medicine. Backed by academic founders and having won recognition from the France 2030 initiative, MSInsight is positioned in the growing market for companion diagnostics and biomarker-driven oncology.

View full company profile

Therapeutic Areas